|
Affiliation |
Faculty of Medicine School of Medicine Department of Developmental and Urological-Reproductive Medicine, Urology |
|
Title |
Assistant Professor |
|
External Link |
|
NAGAI Takahiro
|
|
|
Papers 【 display / non-display 】
-
A case of primary aldosteronism with excessive secretion of renin that was unmasked by kidney transplantation. Reviewed
Fujimoto K, Hisanaga S, Kuroda S, Kodama K, Sugiyama F, Kikuchi M, Kita T, Yamashita A, Nagai T, Kamimura T, Kaikita K, Imamura T, Fujimoto S
CEN case reports 2023.4
Language：English Publishing type：Research paper (scientific journal)
-
Nagai T., Terada N., Fujii M., Nagata Y., Nakahara K., Mukai S., Okasho K., Kamiyama Y., Akamatsu S., Kobayashi T., Iida K., Denawa M., Hagiwara M., Inoue T., Ogawa O., Kamoto T.
Cancer Reports 6 ( 2 ) 2023.2
Publishing type：Research paper (scientific journal) Publisher：Cancer Reports
Background: Several treatment strategies use upfront chemotherapy or androgen receptor axis-targeting therapies for metastatic prostate cancer. However, there are no useful biomarkers for selecting appropriate patients who urgently require these treatments. Methods: Novel patient-derived xenograft (PDX) castration-sensitive and -resistant models were established and gene expression patterns were comprehensively compared. The function of a gene highly expressed in the castration-resistant models was evaluated by its overexpression in LNCaP prostate cancer cells. Protein expression in the tumors and serum of patients was examined by immunohistochemistry and ELISA, and correlations with castration resistance were analyzed. Results: Expression of the α2 chain of interleukin-13 receptor (IL13Rα2) was higher in castration-resistant PDX tumors. LNCaP cells overexpressing IL13Rα2 acquired castration resistance in vitro and in vivo. In tissue samples, IL13Rα2 expression levels were significantly associated with castration-resistant progression (p < 0.05). In serum samples, IL13Rα2 levels could be measured in 5 of 28 (18%) castration-resistant prostate cancer patients. Conclusion: IL13Rα2 was highly expressed in castration-resistant prostate cancer PDX models and was associated with the castration resistance of prostate cancer cells. It might be a potential tissue and serum biomarker for predicting castration resistance in prostate cancer patients.
DOI： 10.1002/cnr2.1701
-
Kawasoe C., Miyamoto Y., Ito K., Murashima T., Nagai T., Takamori H., Kiwaki T., Kamimura T., Mukai S., Kamoto T.
Research and Reports in Urology 15 447 - 452 2023
Publishing type：Research paper (scientific journal) Publisher：Research and Reports in Urology
Epithelioid angiomyolipoma (EAML) is a rare variant of AML with malignant potential. It is occasionally difficult to distinguish EAML from renal cell carcinoma (RCC) on imaging. A 72-year-old woman was admitted to our hospital for the treatment of a left renal tumor with relatively high blood flow and a tumor thrombus extending to the inferior vena cava, suggesting RCC. The patient underwent presurgical combination therapy with axitinib and pembrolizumab. This treatment significantly shortened the thrombus, and radical nephrectomy was performed. The pathological findings were compatible with EAML, and the treatment effects were observed. We report a case treated pre-surgically with a combined therapy of pembrolizumab and axitinib, with a favorable response as a treatment option for EAML.
DOI： 10.2147/RRU.S425887
-
Identification of the α2 chain of interleukin-13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient-derived xenograft models Reviewed
永井 崇敬
Cancer reports 2022.8
Authorship：Lead author Publishing type：Doctoral thesis
-
Pleiotropic effects of probenecid on three-dimensional cultures of prostate cancer cells Reviewed
Uwada J., Mukai S., Terada N., Nakazawa H., Islam M.S., Nagai T., Fujii M., Yamasaki K., Taniguchi T., Kamoto T., Yazawa T.
Life Sciences 278 119554 2021.8
Language：English Publishing type：Research paper (scientific journal) Publisher：Life Sciences
Aims: Chemoresistance remains a persistent challenge in advanced prostate cancer therapy. Probenecid reportedly inhibits multiple drug-efflux transporters; hence, it can be employed as a potential sensitizer for chemotherapy. In the present study, we evaluated the effects of probenecid on three-dimensional (3D)-cultures of prostate cancer cells. Main methods: Prostate cancer cell lines, 22Rv1 and PC-3 were cultured as multicellular tumor spheroids. The effects of probenecid were evaluated using the MTT assay for viability, microscopy for spheroid size, and soft agar colony formation assay for anchorage-independent growth. Key findings: The 3D-cultured 22Rv1 cells were less sensitive to cisplatin and doxorubicin than two-dimensional (2D) cell culture. Co-administration of probenecid at a low (100 or 300 μM), but not high (500 μM), concentration increased the sensitivity to cisplatin or doxorubicin in 22Rv1 spheroids. Probenecid increased the expression of ABCG2, a multidrug resistance transporter, in a dose-dependent manner. Furthermore, treatment with probenecid alone reduced the growth of 22Rv1 spheroids. Conversely, probenecid inhibited spheroid compaction rather than growth inhibition in 3D-cultured PC-3 cells. Moreover, probenecid inhibited colony formation of 22Rv1 and PC-3 cells in soft agar, as well as downregulated focal adhesion kinase (FAK), a crucial factor in anchorage-independent growth. Significance: In 3D-cultured prostate cancer cells, probenecid demonstrated pleiotropic effects such as chemosensitization, growth suppression, inhibition of spheroid compaction, and suppression of anchorage-independent growth. Elucidating the detailed mechanism underlying these probenecid actions could result in the identification of novel therapeutic targets toward the advanced prostate cancer.
Presentations 【 display / non-display 】
-
膀胱膣瘻及び尿管膣漏に対しPure Laparoscopic surgeryで修復術を行った一例
膀胱膣瘻及び尿管膣漏に対しPure Laparoscopic surgeryで修復術を行った一例
第36回日本内視鏡外科学会 2023.12.8
Event date： 2023.12.7 - 2023.12.9
Presentation type：Oral presentation (general)
-
術前化学療法が奏功したリンパ節転移を 伴う尿道扁平上皮癌の一例
永井崇敬，月野浩昌，村嶋隆哉，三宅那央，藤井将人，武田将司，佐藤俊介，山崎浩司， 上別府豊治，上村敏雄，向井尚一郎，賀本敏行
第 68 回西日本泌尿器科学会総会
Event date： 2016.11.26
Language：Japanese Presentation type：Oral presentation (general)
-
尿路上皮癌に対して GN（gemcitabine+nedaplatine）療法を行った 6 例．
永井崇敬，山崎浩司，藤井将人，武田将司，佐藤俊介，月野浩昌，向井尚一郎，上村敏雄， 賀本敏行
第 54回日本癌治療学会学術集会
Event date： 2016.10.21
Language：Japanese Presentation type：Oral presentation (general)
-
膀胱粘膜下腫瘍の 2 例
永井崇敬，秋山裕，三宅那央，藤井将人，武田将司，佐藤俊介，山崎浩司，上別府豊治， 月野浩昌，上村敏雄，向井尚一郎，賀本敏行：
第 130 回日本泌尿器科学会鹿児島地方会，
Event date： 2016.7.9
Language：Japanese Presentation type：Oral presentation (general)
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
転移性CRPCにおける、HGF/METパスウェイを標的とした新規治療法の開発
Grant number：23K08737 2023.04 - 2026.03
独立行政法人日本学術振興会 科学研究費基金 基盤研究（C）
Authorship：Coinvestigator(s)